Bharat Biotech and Bilthoven Biologicals Collaborate to Strengthen Oral Polio Vaccine Production

2 Apr 2024 , 02:26 PM

Bharat Biotech and Bilthoven Biologicals B.V. (BBio), a subsidiary of Serum Institute of India Private Limited based in the Netherlands, have partnered to enhance the production and supply security of Oral Polio Vaccines (OPV).

A formal agreement has been inked between BBIL and BBio, wherein BBIL will procure drug substances for the production of oral polio vaccines to be distributed both within India and globally.

Under this collaboration, BBIL and BBio will work together to acquire the necessary regulatory approvals and licenses for commercial OPV manufacturing in India, utilizing drug substances manufactured by Bilthoven Biologicals in the Netherlands.

Adar Poonawalla, CEO of Serum Institute of India, expressed enthusiasm about reinforcing global polio vaccine supply, aiming to eradicate polio worldwide and reduce its impact on vulnerable populations.

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, highlighted the integral role of oral polio vaccines in India’s Universal Immunization Program (UIP) and emphasized the collaboration’s significance in ensuring a secure OPV supply to support the nation’s polio eradication mission.

As India progresses towards the critical phase of global polio eradication, this collaboration is poised to contribute significantly to the endeavor of creating a polio-free world.

For feedback and suggestions, write to us at [e-mail]